Bicocca Open Archive

Logo unimib boa
COLOMBO, NICOLETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.758
EU - Europa 9.196
AS - Asia 6.407
SA - Sud America 408
AF - Africa 67
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 28
Totale 38.894
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.352
SG - Singapore 2.304
RU - Federazione Russa 2.106
HK - Hong Kong 1.674
CN - Cina 1.525
IT - Italia 1.519
IE - Irlanda 1.377
UA - Ucraina 1.019
SE - Svezia 960
DE - Germania 690
GB - Regno Unito 453
CA - Canada 373
BR - Brasile 344
FI - Finlandia 295
AT - Austria 254
ID - Indonesia 252
VN - Vietnam 183
FR - Francia 149
NL - Olanda 138
IN - India 109
JP - Giappone 102
TR - Turchia 88
DK - Danimarca 61
ZA - Sudafrica 33
BE - Belgio 30
ES - Italia 30
MX - Messico 26
KR - Corea 25
TW - Taiwan 25
AU - Australia 24
EU - Europa 20
AR - Argentina 18
IR - Iran 18
RO - Romania 18
CL - Cile 14
PK - Pakistan 13
BG - Bulgaria 10
CH - Svizzera 10
GR - Grecia 10
PL - Polonia 10
PH - Filippine 9
CO - Colombia 8
UZ - Uzbekistan 8
A2 - ???statistics.table.value.countryCode.A2??? 7
BD - Bangladesh 7
CZ - Repubblica Ceca 7
KE - Kenya 7
MA - Marocco 7
NO - Norvegia 7
PT - Portogallo 7
EC - Ecuador 6
IL - Israele 6
IQ - Iraq 6
PE - Perù 6
UY - Uruguay 6
KZ - Kazakistan 5
LB - Libano 5
MD - Moldavia 5
MK - Macedonia 5
NZ - Nuova Zelanda 5
TH - Thailandia 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
EG - Egitto 4
MU - Mauritius 4
MY - Malesia 4
NP - Nepal 4
RS - Serbia 4
SA - Arabia Saudita 4
HU - Ungheria 3
KG - Kirghizistan 3
LU - Lussemburgo 3
QA - Qatar 3
TN - Tunisia 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
CU - Cuba 2
DZ - Algeria 2
HR - Croazia 2
JM - Giamaica 2
JO - Giordania 2
LK - Sri Lanka 2
LT - Lituania 2
MO - Macao, regione amministrativa speciale della Cina 2
PY - Paraguay 2
SN - Senegal 2
SY - Repubblica araba siriana 2
VE - Venezuela 2
AM - Armenia 1
AO - Angola 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GH - Ghana 1
GI - Gibilterra 1
GT - Guatemala 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 38.882
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.337
Woodbridge 2.684
Fairfield 2.357
Houston 1.888
Hong Kong 1.653
Singapore 1.425
Dublin 1.296
Jacksonville 1.191
Ashburn 1.053
Wilmington 1.007
Seattle 889
Cambridge 787
Dearborn 736
Chandler 695
Princeton 639
New York 595
Santa Clara 429
Milan 402
Lawrence 315
Altamura 290
Nanjing 279
Frankfurt am Main 269
Jakarta 236
Lachine 202
Beijing 199
Vienna 186
San Diego 143
Moscow 135
Andover 125
Nuremberg 121
Shanghai 112
Guangzhou 111
Boardman 103
Dong Ket 96
Toronto 90
London 86
Nanchang 85
Hamburg 75
Rome 75
Shenyang 70
Council Bluffs 69
Falls Church 69
Helsinki 67
Hebei 60
Tianjin 57
Ottawa 55
Los Angeles 51
Norwalk 51
Changsha 50
Chicago 50
Mountain View 49
Hangzhou 42
Jiaxing 42
Redmond 41
Huizen 38
São Paulo 36
Fremont 31
Tokyo 31
Jinan 29
Kunming 29
Zhengzhou 26
University Park 25
Pune 23
Lappeenranta 21
Brussels 19
Hanoi 18
Hyderabad 18
Ningbo 18
Gaithersburg 17
Turin 17
Taipei 16
Trento 16
Dallas 15
Detroit 15
San Mateo 15
Silver Spring 15
Hefei 14
Lissone 13
Chengdu 12
Naples 12
Washington 12
Amsterdam 11
Bologna 11
Hounslow 11
Kilburn 11
Padova 11
Rio de Janeiro 11
Florence 10
Groningen 10
Johannesburg 10
Lecco 10
Melbourne 10
Monza 10
Palermo 10
Phoenix 10
Arezzo 9
Belo Horizonte 9
Madrid 9
Sacramento 9
Shenzhen 9
Totale 27.961
Salva come PNG Salva come JPEG
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 497
Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220) 271
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer 261
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 227
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 224
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer 215
Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study 214
CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells 207
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 206
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 200
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 195
FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer 194
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study 192
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series 182
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 181
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12 178
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation 176
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial 175
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer 170
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial 169
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 167
Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum 165
Low-dose oral etoposide in epithelial cancer of the ovary 160
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial 159
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 158
Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells 158
Reply to M.L. Friedlander et al 158
Neoadjuvant chemotherapy in cervical cancer: An update 158
Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB 157
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 156
Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: A single institution prospective series 156
Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy 155
The disposition of carboplatin in ovarian cancer patients 155
Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis 155
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial 155
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer 154
A reassessment of the role of second-look laparotomy in advanced ovarian cancer 154
Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients 154
Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors 154
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study 153
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 153
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer intergroup 153
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin 153
Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients 152
Trabectedin as single agent in relapsed advanced ovarian cancer: Results from a retrospective pooled analysis of three phase II trials 152
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 152
Antibody-dependent and -independent cytotoxicity of human mononuclear phagocytes: defective stimulation of tumoricidal activity in milk macrophages 152
The role of surgery in gestational trophoblastic disease 151
DR antigen expression on ovarian carcinoma cells does not correlate with their capacity to elicit an autologous proliferative response 151
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge 151
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups 151
Chemo-conization in early cervical cancer 149
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study 149
Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells 148
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study 148
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion 147
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 147
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens 147
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer 146
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 146
Treatment of advanced ovarian cancer (OC): A randomized trial comparing different platinum (P) combinations 145
Tumor-derived chemotactic factor(s) from human ovarian carcinoma: evidence for a role in the regulation of macrophage content of neoplastic tissues 144
Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience 143
Methotrexate with citrovorum factor in low-risk gestational trophoblastic tumor 142
Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case series 142
Aggressive angiomyxoma of the vulva 141
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 141
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 141
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial 141
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 140
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer 140
Robotic Surgery: Changing the Surgical Approach for Endometrial Cancer in a Referral Cancer Center 139
Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary 139
Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer 139
Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives 139
Robotic Versus Open Radical Hysterectomy in Women With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: A Single-institution Experience of Surgical and Oncologic Outcomes 138
Fertility-sparing surgery in epithelial ovarian cancer: A systematic review of oncological issues 138
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 138
Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis 138
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial 138
Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients 137
Are monoclonal antibodies a safe treatment for cancer during pregnancy? 137
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status 137
Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients 136
Fertility-Sparing Options in Young Women with Cervical Cancer 136
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 136
Optimal treatment of early-stage ovarian cancer 135
Optimizing treatment of the partially platinum-sensitive ovarian cancer patient 135
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study 135
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 134
Early oral versus "traditional" postoperative feeding in gynecologic oncology patients undergoing intestinal resection: A randomized controlled trial 134
Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit 134
Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities 133
Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer 132
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial 132
Defective natural killer activity within human ovarian tumors: Low numbers of morphologically defined effectors present in situ 131
Overexpression of p185 is not related to erbB2 amplification in ovarian cancer 131
Adult granulosa cell tumours of the ovary 131
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer 131
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial 131
Totale 15.957
Salva come PNG Salva come JPEG
Categoria #
all - tutte 166.095
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 166.095
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020802 0 0 0 0 0 0 0 0 0 260 422 120
2020/20214.780 335 227 446 451 535 396 481 511 396 478 199 325
2021/20223.002 181 245 348 237 184 196 168 209 186 250 231 567
2022/20234.033 665 1.028 274 226 247 729 59 327 243 66 95 74
2023/20244.164 98 105 176 111 637 1.033 755 107 525 117 68 432
2024/20259.181 713 1.688 492 616 1.039 526 998 405 1.286 1.418 0 0
Totale 40.211